DZ Bank upgraded Gilead (GILD) to Buy from Hold with a $108 price target
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Gilead Sciences: Strong Performance and Growth Potential in HIV and Oncology Segments Boost Buy Rating
- Gilead Sciences’ Earnings Call: Strong Growth Amid Challenges
- CVS Health, Lyft report Q4 results: Morning Buzz
- Early notable gainers among liquid option names on February 12th
- Gilead price target raised to $100 from $95 at TD Cowen